Real‐world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases

One of the more recently investigated adverse long‐term side effects of gonadotropin‐releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease (CVD). Studies suggest lower risk of CVD following GnRH antagonists (degarelix) than GnRH agonists. This protocol describes preci...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Gincy, Scailteux, Lucie‐Marie, Garmo, Hans, Balusson, Frédéric, Cardwell, Christopher, Coster, Greet De, Schutter, Harlinde De, Kuiper, Josephina G., McMenamin, Úna, Verbeeck, Julie, Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850363/
https://www.ncbi.nlm.nih.gov/pubmed/30776136
http://dx.doi.org/10.1111/fcp.12454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850363/
https://www.ncbi.nlm.nih.gov/pubmed/30776136
http://dx.doi.org/10.1111/fcp.12454

Ejemplares similares